Why Digital Health Still Struggles to Reach Enterprise Scale

For much of the past decade, digital health has focused on building better products. AI-powered diagnostics, remote monitoring, automation platforms, and virtual care solutions have attracted billions in investment and generated thousands of startups. Yet despite the innovation, relatively few companies have successfully scaled into enterprise-wide healthcare platforms.

Healthcare150's latest proprietary survey suggests the problem is not primarily technological. Among 142 healthcare professionals surveyed, 39% identified navigating health systems as the single biggest obstacle preventing digital health companies from reaching enterprise scale. That ranked ahead of unclear clinical ROI (31%) and weak reimbursement models (30%).

The findings point to an important shift in how the industry should think about commercialization.

The Enterprise Problem Is Operational

Healthcare is unlike almost any other enterprise market.

Selling software into a Fortune 500 company may require approval from IT and finance. Selling into a hospital often requires alignment across clinicians, procurement teams, legal departments, cybersecurity, compliance, executive leadership, and operational stakeholders. Each group measures value differently.

Even products with compelling clinical evidence can spend months navigating procurement processes before implementation begins.

This helps explain why many well-funded digital health companies report strong pilot results but struggle to expand beyond a handful of health systems.

The challenge is no longer proving that technology works. It is proving that organizations can adopt it without disrupting existing workflows.

Clinical Evidence Alone Is No Longer Enough

The survey also found that 31% of respondents cited unclear clinical ROI as the biggest barrier to enterprise adoption.

Healthcare executives increasingly expect more than published studies or promising pilot data. They want measurable financial outcomes.

Questions such as reduced readmissions, lower administrative costs, shorter patient wait times, improved clinician productivity, or measurable revenue improvement have become central to purchasing decisions.

As health systems continue operating under financial pressure, technology investments must compete directly against staffing, capital projects, and other operational priorities.

The implication for digital health companies is straightforward. Clinical validation opens the door, but financial validation often determines whether the contract expands.

Reimbursement Still Matters, But It Is Not the Primary Constraint

Historically, reimbursement has been viewed as the defining challenge for digital health.

While 30% of survey respondents still identified reimbursement as the largest obstacle, it ranked below both enterprise complexity and clinical ROI.

This may reflect a broader maturation of the industry. Many digital health companies now target operational efficiency, workforce productivity, revenue cycle optimization, or administrative automation rather than relying exclusively on reimbursement-driven business models.

Instead of asking whether a solution can be reimbursed, health systems increasingly ask whether it creates measurable enterprise value.

The New Competitive Advantage

The survey suggests that competitive differentiation is shifting away from product features alone.

Companies that successfully scale are increasingly those that simplify implementation, integrate seamlessly with existing electronic health records, minimize disruption to clinicians, and clearly quantify economic value.

In other words, execution has become a product feature.

For investors, this changes how digital health companies should be evaluated. Product innovation remains important, but commercialization capabilities, implementation speed, customer success, and enterprise integration may prove to be stronger predictors of long-term success than technology alone.

Healthcare has never rewarded innovation in isolation. It rewards solutions that fit within the realities of complex delivery systems.

The next generation of digital health leaders will likely be defined less by breakthrough technology than by their ability to navigate healthcare's operational complexity. The companies that win enterprise adoption will not necessarily build the most advanced products. They will build products that health systems can actually buy, deploy, and scale.